SRR8518232
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.400
- ADIPOGENESIS+0.370
- XENOBIOTIC_METABOLISM+0.360
- FATTY_ACID_METABOLISM+0.340
- GLYCOLYSIS+0.340
- CHOLESTEROL_HOMEOSTASIS+0.330
- HYPOXIA+0.300
- PROTEIN_SECRETION+0.300
- ANDROGEN_RESPONSE+0.290
- PEROXISOME+0.280
Top 10 suppressed
- MITOTIC_SPINDLE-0.260
- WNT_BETA_CATENIN_SIGNALING-0.220
- MYOGENESIS-0.160
- KRAS_SIGNALING_DN-0.120
- MYC_TARGETS_V2-0.120
- SPERMATOGENESIS-0.110
- E2F_TARGETS-0.100
- TGF_BETA_SIGNALING-0.040
- HEDGEHOG_SIGNALING-0.030
- APICAL_JUNCTION-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013485 | — | cohortA4 | 0.817 |
| 2 | BS_HV8PFRBR | pilocytic astrocytoma | — | 0.798 |
| 3 | ff02e85e-2f87-4832-aaea-3322db33c57a | — | — | 0.792 |
| 4 | SRR15030885 | — | — | 0.788 |
| 5 | SNU878_LIVER | HCC | — | 0.779 |
| 6 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.779 |
| 7 | fd17af6d-f9d4-4d4f-8487-bf8b97cfe3ab | — | — | 0.774 |
| 8 | SRR15030876 | — | — | 0.771 |
| 9 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.764 |
| 10 | TCGA-49-4494-01A-01R-1206-07 | — | cohortA1 | 0.761 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |